Author Correction: Real-world ANASTASE study of atezolizumab+nab-paclitaxel as first-line treatment of PD-L1-positive metastatic triple-negative breast cancer

被引：0

作者：

Alessandra Fabi

Luisa Carbognin

Andrea Botticelli

Ida Paris

Paola Fuso

Maria Cristina Savastano

Nicla La Verde

Carla Strina

Rebecca Pedersini

Stefania Guarino

Giuseppe Curigliano

Carmen Criscitiello

Mimma Raffaele

Alessandra Beano

Antonio Franco

Maria Rosaria Valerio

Francesco Verderame

Andrea Fontana

Eva Regina Haspinger

Alessia Caldara

Alba Di Leone

Giampaolo Tortora

Diana Giannarelli

Giovanni Scambia

机构：

[1] Fondazione Policlinico Universitario A. Gemelli IRCCS,Precision Medicine Unit in Senology

[2] Fondazione Policlinico Universitario A. Gemelli IRCCS,Division of Gynecology Oncology, Department of Woman and Child Health and Public Health

[3] University of Rome,Medical Oncology Unit, La Sapienza

[4] Medical Oncology Unit,Department of Oncology and Hemato

[5] A.O.U. San Giovanni di Dio e Ruggi D’Aragona,Oncology

[6] Medical Oncology Unit,Department of Medical Oncology1

[7] ASST Fatebenefratelli Sacco PO Luigi Sacco - Polo Universitario,Breast Unit, Department of Women, Children and Public Health Sciences

[8] Medical Oncology Unit Azienda Socio-Sanitaria Territoriale Cremona,Medical Oncology, Department of Translational Medicine and Surgery

[9] Medical Oncology Unit ASST Spedali Civili,Epidemiology and Biostatistics Facility

[10] Medical Oncology Unit Santa Maria della Misericordia Hospital,undefined

[11] University of Milan,undefined

[12] Division of Early Drug Development,undefined

[13] European Institute of Oncology,undefined

[14] IRCCS,undefined

[15] Presidio Cassia Sant’andrea,undefined

[16] Dipartimento Oncologico,undefined

[17] Asl Roma1,undefined

[18] Città della Salute e della Scienza Hospital,undefined

[19] Fondazione Policlinico Universitario Agostino Gemelli IRCCS,undefined

[20] Medical Oncology,undefined

[21] Policlinico Universitario P. Giaccone,undefined

[22] Medical Oncology,undefined

[23] AO Riuniti Villa Sofia,undefined

[24] Cervello,undefined

[25] Medical Oncology Unit 2,undefined

[26] Azienda Ospedaliero-Universitaria Pisana,undefined

[27] Azienda Sanitaria dell’Alto Adige – Ospedale di Merano,undefined

[28] Santa Chiara Hospital,undefined

[29] Medical Oncology,undefined

[30] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined

[31] Università Cattolica del Sacro Cuore,undefined

[32] Fondazione Policlinico Universitario A. Gemelli IRCCS,undefined

[33] Università Cattolica del Sacro Cuore,undefined

来源：

npj Breast Cancer | / 10卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[31] Phase Ib study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)
Schmid, Peter
Loirat, Delphine
Savas, Peter
Espinosa, Enrique
Boni, Valentina
Italiano, Antoine
White, Shane
Singel, Stina M.
Withana, Nimali
Mani, Aruna
Li, Suwen
Harris, Adam
Wongchenko, Matthew
Sablin, Marie
CANCER RESEARCH, 2019, 79 (13)
[32] Real-world outcomes of first-line pembrolizumab monotherapy for PD-L1-positive (TPS ≥50%) metastatic non-small cell lung cancer (NSCLC)
Velcheti, Vamsidhar
Chandwani, Sheenu
Chen, Xin
Pietanza, M. Catherine
Burke, Thomas
CANCER RESEARCH, 2019, 79 (13)
[33] Real-world analysis of taxane use in the first-line setting and prior comorbidities among female metastatic triple-negative breast cancer patients
Lin, Shih-Wen
Thakrar, Dixa
Simpson, Joseph
Funke, Roel
Chui, Stephen
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 97 - 98
[34] Ixabepilone Alone or With Cetuximab as First-Line Treatment for Advanced/Metastatic Triple-Negative Breast Cancer
Tredan, Olivier
Campone, Mario
Jassem, Jacek
Vyzula, Rostislav
Coudert, Bruno
Pacilio, Carmen
Prausova, Jana
Hardy-Bessard, Anne-Claire
Arance, Ana
Mukhopadhyay, Pralay
Aloe, Alessandra
Roche, Henri
CLINICAL BREAST CANCER, 2015, 15 (01) : 8 - 15
[35] Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer
Yoshikawa, Katsuhiro
Ishida, Mitsuaki
Yanai, Hirotsugu
Tsuta, Koji
Sekimoto, Mitsugu
Sugie, Tomoharu
BMC CANCER, 2021, 21 (01)
[36] Prognostic significance of PD-L1-positive cancer-associated fibroblasts in patients with triple-negative breast cancer
Katsuhiro Yoshikawa
Mitsuaki Ishida
Hirotsugu Yanai
Koji Tsuta
Mitsugu Sekimoto
Tomoharu Sugie
BMC Cancer, 21
[37] The effectiveness of nab-paclitaxel plus gemcitabine and gemcitabine monotherapy in first-line metastatic pancreatic cancer treatment: A real-world evidence
Prejac, Juraj
Hamzic, Dora Tomek
Librenjak, Niksa
Gorsic, Irma
Kekez, Domina
Plestina, Stjepko
MEDICINE, 2022, 101 (39) : E30566
[38] First-line gemcitabine plus nab-paclitaxel versus FOLFIRINOX for metastatic pancreatic cancer in a real-world population
Hatashima, Alycia
Arango, Matthew J.
Reardon, Joshua
Freeman, Tracelyn
Williams, Terence
McLaughlin, Eric M.
Abushahin, Laith
FUTURE ONCOLOGY, 2022, 18 (20) : 2521 - 2532
[39] Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC)
Schmid, P.
Kuemmel, S.
Loirat, D.
Savas, P.
Espinosa, E.
Boni, V
Italiano, A.
White, S.
Singel, S.
Withana, N.
Mani, A.
Li, S.
Harris, A.
Wongchenko, M.
Sablin, M.
GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (06) : E44 - E45
[40] Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1
Huang, Min
O'Shaughnessy, Joyce
Haiderali, Amin
Pan, Wilbur
Hu, Peter
Chaudhuri, Mitashri
De Tilleghem, Celine Le Bailly
Cappoen, Nicolas
Fasching, Peter A.
EUROPEAN JOURNAL OF CANCER, 2022, 177 : 45 - 52

← 1 2 3 4 5 →